Brief: JCR Pharmaceuticals Initiates Phase III Clinical Trial Of JR-142 In Japan
20/12/2024 19:17
Dec 20 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* JCR PHARMACEUTICALS INITIATES PHASE III CLINICAL TRIAL OF
JR-142
IN JAPAN, A LONG-ACTING GROWTH HORMONE THERAPY
Source text: ID:nBwbLJpkVa
Further company coverage: 4552.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results